

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2

New England Journal of Medicine

385, e83

DOI: [10.1056/nejmoa2114114](https://doi.org/10.1056/nejmoa2114114)

Citation Report

#	ARTICLE	IF	CITATIONS
8	How can we prepare for this autumn and winter?. Osong Public Health and Research Perspectives, 2021, 12, 275-277.	0.7	0
13	Covid-19: Antibody levels fall after second Pfizer dose, but protection against severe disease remains, studies indicate. BMJ, The, 2021, 375, n2481.	3.0	4
14	Boosters appear effective, but are they always needed?. Lancet, The, 2021, 398, 2055-2057.	6.3	3
16	COVID-19 vaccine " Long term immune decline and breakthrough infections. Vaccine, 2021, 39, 6984-6989.	1.7	77
18	Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. JAMA - Journal of the American Medical Association, 2021, 326, 1930.	3.8	140
20	Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination. JAMA - Journal of the American Medical Association, 2021, 326, 2018.	3.8	64
21	SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science, 2022, 375, 331-336.	6.0	202
22	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 12081.	1.8	21
23	BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature Medicine, 2021, 27, 2136-2143.	15.2	346
24	BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Science Immunology, 2021, 6, eab15344.	5.6	166
25	Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2. Journal of Medical Economics, 2021, 24, 1248-1260.	1.0	38
26	Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination. Vaccines, 2021, 9, 1325.	2.1	8
27	Limited Impact of Delta Variant's Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population. Viruses, 2021, 13, 2405.	1.5	3
29	Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine, 2021, 385, e92.	13.9	53
30	mRNA vaccines against COVID-19: a showcase for the importance of microbial biotechnology. Microbial Biotechnology, 2022, 15, 135-148.	2.0	9
31	Auricular acupressure for adverse events following immunization related to COVID-19 vaccine injection: study protocol for a multicenter, three-arm, blinded randomized controlled trial. Trials, 2021, 22, 857.	0.7	1
33	Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Global Epidemiology, 2021, 3, 100068.	0.6	30
36	COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. Healthcare (Switzerland), 2021, 9, 1566.	1.0	57

#	ARTICLE	IF	CITATIONS
37	Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2022, 13, 100278.	3.0	109
39	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 2258-2276.	6.3	519
40	Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults. <i>Vaccine</i> , 2022, 40, 524-530.	1.7	50
41	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
42	Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. <i>Lancet</i> , The, 2021, 398, 2126-2128.	6.3	1,057
43	Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era. <i>Lancet Microbe</i> , The, 2022, 3, e4-e5.	3.4	45
45	Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
50	Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections. <i>Nature Communications</i> , 2022, 13, 532.	5.8	53
52	Longitudinal waning of mRNA vaccine-induced neutralizing antibodies against SARS-CoV-2 detected by an LFIA rapid test. <i>Antibody Therapeutics</i> , 2022, 5, 55-62.	1.2	6
53	Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection. <i>Med</i> , 2022, 3, 28-41.e8.	2.2	19
54	Effectiveness of mRNA COVID-19 Vaccination Against SARS-CoV-2 Infection and COVID-19 Disease in Sicily Over an Eight-Month Period. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
57	Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. <i>BMC Medicine</i> , 2022, 20, 32.	2.3	7
58	Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. <i>Vaccines</i> , 2022, 10, 153.	2.1	20
59	SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
60	Do health-care workers need a COVID-19 vaccine booster?. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 20.	4.6	5
62	Vaccination strategies and transmission of COVID-19: Evidence across advanced countries. <i>Journal of Health Economics</i> , 2022, 82, 102589.	1.3	23
63	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
64	SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103417.	0.9	16

#	ARTICLE	IF	CITATIONS
65	Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines. <i>New England Journal of Medicine</i> , 2022, 386, 340-350.	13.9	501
67	Vaccine effectiveness against severe acute respiratory infections (SARI) COVID-19 hospitalisations estimated from real-world surveillance data, Slovenia, October 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	4
68	Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 799-800.	13.9	58
69	Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: interim results from a prospective open-label study. <i>Emerging Microbes and Infections</i> , 2022, 11, 639-647.	3.0	36
70	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment “ Meeting report from an isirv-WHO virtual conference. <i>Antiviral Research</i> , 2022, 197, 105227.	1.9	19
71	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. <i>Cell Reports</i> , 2022, 38, 110235.	2.9	35
72	Viral replication dynamics could critically modulate vaccine effectiveness and should be accounted for when assessing new SARS-CoV-2 variants. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 366-367.	1.5	4
73	Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 639.	3.8	539
75	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. <i>Vaccines</i> , 2022, 10, 140.	2.1	7
77	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. <i>New England Journal of Medicine</i> , 2022, 386, 933-941.	13.9	238
78	COVID-19 Vaccines. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 481-494.	1.9	13
79	Omicron: the highly mutational COVID-19 variant with immune escape. <i>Pan African Medical Journal</i> , 2022, 41, 84.	0.3	2
80	Attitudes of Poles towards the COVID-19 Vaccine Booster Dose: An Online Survey in Poland. <i>Vaccines</i> , 2022, 10, 68.	2.1	22
82	The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21485.	0.2	10
83	Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1293-1305.	1.6	28
87	Modeling the omicron wave in France in early 2022: Balancing herd immunity with protecting the most vulnerable. <i>Journal of Travel Medicine</i> , 2022, , .	1.4	6
88	Bayesian Inference of State-Level COVID-19 Basic Reproduction Numbers across the United States. <i>Viruses</i> , 2022, 14, 157.	1.5	17
89	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	2.2	38

#	ARTICLE	IF	CITATIONS
90	Vaccination Induces Stronger Spike Immunity and Better Protection Against SARS-CoV-2 Infection in COVID-19 Recovered Subjects than in Naïve Individuals. SSRN Electronic Journal, 0, , .	0.4	0
91	Impact of vaccination on the COVID-19 pandemic in U.S. states. Scientific Reports, 2022, 12, 1554.	1.6	54
92	Waning mRNA-1273 Vaccine Effectiveness against SARS-CoV-2 Infection in Qatar. New England Journal of Medicine, 2022, 386, 1091-1093.	13.9	83
93	The Unintended Consequences of COVID-19 Vaccine Policy: Why Mandates, Passports, and Segregated Lockdowns May Cause more Harm than Good. SSRN Electronic Journal, 0, , .	0.4	4
94	Optimal Timing of COVID-19 Vaccination in the Peri-Transplant Period: A Single Institution Case Series. Transplantation Proceedings, 2022, 54, 1409-1411.	0.3	1
95	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. Biomedicines, 2022, 10, 338.	1.4	21
96	Boosting immunity after CoronaVac. Lancet, The, 2022, 399, 496-497.	6.3	4
97	Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article. International Journal of Surgery, 2022, 98, 106233.	1.1	21
98	Vaccination status among patients with the need for emergency hospitalizations related to COVID-19. American Journal of Emergency Medicine, 2022, 54, 102-106.	0.7	6
99	SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	6
100	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. JCI Insight, 2022, 7, .	2.3	12
102	SARS-CoV-2 infection and vaccination trigger long-lived B and CD4+ T lymphocytes with implications for booster strategies. Journal of Clinical Investigation, 2022, 132, .	3.9	30
103	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet, The, 2022, 399, 814-823.	6.3	196
104	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. Emerging Microbes and Infections, 2022, 11, 585-592.	3.0	50
105	The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell, 2022, 185, 447-456.e11.	13.5	736
106	Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. Journal of Clinical Pharmacology, 2022, 62, 291-303.	1.0	23
107	Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults. Frontiers in Aging, 2022, 3, .	1.2	9
108	Characterizing the effective reproduction number during the COVID-19 pandemic: Insights from Qatar's experience. Journal of Global Health, 2022, 12, 05004.	1.2	7

#	ARTICLE	IF	CITATIONS
110	Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic Hemodialysis. <i>Clinical Infectious Diseases</i> , 2022, 75, e617-e622.	2.9	10
111	SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. <i>Environmental Research</i> , 2022, 209, 112911.	3.7	181
112	Estimated Effectiveness of COVID-19 Messenger RNA Vaccination Against SARS-CoV-2 Infection Among Older Male Veterans Health Administration Enrollees, January to September 2021. <i>JAMA Network Open</i> , 2021, 4, e2138975.	2.8	14
113	COV-BOOST: evidence to support rapid booster deployment. <i>Lancet, The</i> , 2021, 398, 2209-2211.	6.3	7
114	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 0, , .	13.7	104
115	The germinal centre B cell response to SARS-CoV-2. <i>Nature Reviews Immunology</i> , 2022, 22, 7-18.	10.6	150
116	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
117	Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. <i>Nature</i> , 2022, 602, 654-656.	13.7	928
118	BNT162b2 Vaccine Booster and Mortality Due to Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 2413-2420.	13.9	288
119	Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e683-e691.	2.9	48
120	Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e185-e190.	2.9	60
125	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. <i>Microbial Biotechnology</i> , 2022, 15, 721-737.	2.0	41
126	Introduction and expansion of the SARS-CoV-2 B.1.1.7 variant and reinfections in Qatar: A nationally representative cohort study. <i>PLoS Medicine</i> , 2021, 18, e1003879.	3.9	54
127	SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. <i>Annals of Internal Medicine</i> , 2022, 175, 371-378.	2.0	55
128	A low proportion of asymptomatic COVID-19 patients with the Delta variant infection by viral transmission through household contact at the time of confirmation in Ibaraki, Japan. <i>Global Health & Medicine</i> , 2022, , .	0.6	2
129	ChAdOx1 nCoV-19, BNT162b2 and CoronaVac Vaccines Do Not Induce as Strong Neutralising Antibodies with Broad Variant Protection as Infection and Suggest Vaccines that Induce Broader Sterilising Immunity are Essential to Stop the Pandemic. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
130	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, , .	0.2	1
131	Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
132	Vaccination provides protection from respiratory deterioration and death among hospitalized COVID-19 patients: Differences between vector and mRNA vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 2849-2854.	2.5	19
133	Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 557-565.	5.2	44
134	The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. <i>Annals of Internal Medicine</i> , 2022, 175, 674-681.	2.0	45
135	Waning effectiveness of COVID-19 vaccines. <i>Lancet</i> , 2022, 399, 771-773.	6.3	35
136	Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: A retrospective cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100198.	1.5	62
137	Longevity and Clinical Effectiveness of the Humoral and Cellular Responses to SARS-CoV-2 Vaccination in Hemodialysis Patients. <i>Kidney International Reports</i> , 2022, 7, 1103-1107.	0.4	8
139	mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 607-612.	1.5	7
140	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
141	Waning COVID-19 vaccine effectiveness in Japan. <i>Drug Discoveries and Therapeutics</i> , 2022, 16, 30-36.	0.6	6
144	Vaccination Against SARS-CoV-2 Is Associated With a Lower Viral Load and Likelihood of Systemic Symptoms. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac066.	0.4	17
146	Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. <i>Vaccines</i> , 2022, 10, 323.	2.1	1
147	Protection Duration of COVID-19 Vaccines: Waning Effectiveness and Future Perspective. <i>Frontiers in Microbiology</i> , 2022, 13, 828806.	1.5	17
148	Understanding how fast SARS-CoV-2 variants transmit from household studies. <i>Lancet Infectious Diseases</i> , 2022, 22, 564-565.	4.6	3
149	Modeling Vaccine Efficacy for COVID-19 Outbreak in New York City. <i>Biology</i> , 2022, 11, 345.	1.3	15
150	Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 285.	2.1	13
151	Predicting the Effects of Waning Vaccine Immunity Against COVID-19 through High-Resolution Agent-Based Modeling. <i>Advanced Theory and Simulations</i> , 2022, 5, 2100521.	1.3	11
152	Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. <i>New England Journal of Medicine</i> , 2022, 386, 1207-1220.	13.9	452
153	Comparison of vaccine efficacy must be based on good clinical data. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 20, 100410.	1.3	1

#	ARTICLE	IF	CITATIONS
154	The changing epidemiology of SARS-CoV-2. <i>Science</i> , 2022, 375, 1116-1121.	6.0	177
155	Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021. <i>JAMA Network Open</i> , 2022, 5, e225018.	2.8	11
156	Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination. <i>Vaccine</i> , 2022, 40, 2652-2655.	1.7	26
157	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. <i>Lancet</i> , 2022, 399, 924-944.	6.3	752
158	Physicians' Perspective on Vaccine-Hesitancy at the Beginning of Israel's COVID-19 Vaccination Campaign and Public's Perceptions of Physicians' Knowledge When Recommending the Vaccine to Their Patients: A Cross-Sectional Study. <i>Frontiers in Public Health</i> , 2022, 10, 855468.	1.3	12
159	Factors Related to Non-compliance With Non-pharmaceutical Interventions to Mitigate the Spread of SARS-CoV-2: Results From a Survey in the Swiss General Adult Population. <i>Frontiers in Public Health</i> , 2022, 10, 828584.	1.3	2
160	Impact of the Sinopharm's BBIBP-CoV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). <i>Vaccine</i> , 2022, 40, 2003-2010.	1.7	39
161	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
162	Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. <i>Frontiers in Immunology</i> , 2022, 13, 842912.	2.2	31
164	Coronavirus Genomes and Unique Mutations in Structural and Non-Structural Proteins in Pakistani SARS-CoV-2 Delta Variants during the Fourth Wave of the Pandemic. <i>Genes</i> , 2022, 13, 552.	1.0	13
165	Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period. <i>Vaccines</i> , 2022, 10, 426.	2.1	6
166	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1032.	3.8	57
167	Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. <i>International Journal of Infectious Diseases</i> , 2022, 119, 69-76.	1.5	48
169	Neutralizing Antibodies Responses against SARS-CoV-2 in a Sardinian Cohort Group Up to 9 Months after BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 531.	2.1	5
170	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 1910-1921.	13.9	215
171	Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study. <i>Antibiotics</i> , 2022, 11, 345.	1.5	15
172	Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose. <i>Frontiers in Public Health</i> , 2022, 10, 847384.	1.3	12
173	Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. <i>New England Journal of Medicine</i> , 2022, 386, 1804-1816.	13.9	311

#	ARTICLE	IF	CITATIONS
174	Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies. <i>Vaccines</i> , 2022, 10, 469.	2.1	8
175	Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. <i>International Journal of Infectious Diseases</i> , 2022, 119, 87-94.	1.5	35
176	Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population. <i>Clinical Infectious Diseases</i> , 2022, 75, e579-e584.	2.9	17
179	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	3.4	48
180	Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273. <i>Microbiology Spectrum</i> , 2022, 10, e0270221.	1.2	3
181	Surfing Corona waves “instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
182	Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. <i>Vaccines</i> , 2022, 10, 479.	2.1	9
183	Neutralizing antibody responses 300 days after SARS-CoV-2 infection and induction of high antibody titers after vaccination. <i>European Journal of Immunology</i> , 2022, 52, 810-815.	1.6	9
184	Assessment of Clinical Effectiveness of BNT162b2 COVID-19 Vaccine in US Adolescents. <i>JAMA Network Open</i> , 2022, 5, e220935.	2.8	20
185	Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2404-2414.	2.7	34
187	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
188	Timely Monitoring COVID-19 Vaccine Protection, Berlin, Germany, April 15th to December 15th, 2021. <i>International Journal of Public Health</i> , 2022, 67, 1604633.	1.0	0
189	Vaccination and immunotherapies in neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2022, 18, 289-306.	4.9	27
190	Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e356-e365.	4.7	41
191	COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1002-1010.	4.6	192
192	There is nothing exempt from the peril of mutation “The Omicron spike. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112756.	2.5	11
193	Long-term effects of SARS-CoV-2 vaccination in the nursing home setting. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 1336-1341.	1.3	7
194	BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection?. <i>EMBO Molecular Medicine</i> , 2022, 14, e15326.	3.3	30

#	ARTICLE	IF	CITATIONS
195	SARS-CoV-2 variants of concern and vaccine escape, from Alpha to Omicron and beyond. Expert Review of Respiratory Medicine, 2022, 16, 499-502.	1.0	10
196	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e545-e551.	2.9	130
197	Vaccination against SARS-CoV-2 infection among vulnerable and marginalised population groups in Denmark: A nationwide population-based study. Lancet Regional Health - Europe, The, 2022, 16, 100355.	3.0	20
199	ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. Endoscopy, 2022, 54, 211-216.	1.0	12
201	The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS). Vaccines, 2022, 10, 9.	2.1	11
206	Highly Sensitive and Specific SARS-CoV-2 Serological Assay Using a Magnetic Modulation Biosensing System. Biosensors, 2022, 12, 7.	2.3	3
209	Why promoting a COVID-19 vaccine booster dose?. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100967.	0.6	18
214	Nosocomial Outbreak by Delta Variant From a Fully Vaccinated Patient. Journal of Korean Medical Science, 2022, 37, e133.	1.1	8
215	Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel. Clinical Infectious Diseases, 2023, 76, 113-118.	2.9	4
216	Association of Psychiatric Disorders With Incidence of SARS-CoV-2 Breakthrough Infection Among Vaccinated Adults. JAMA Network Open, 2022, 5, e227287.	2.8	19
217	Outbreak of delta variant SARS-CoV-2 virus on a psychogeriatric ward in Helsinki, Finland, August 2021; two-dose vaccination reduces mortality and disease severity amongst the elderly.. Epidemiology and Infection, 2022, , 1-14.	1.0	0
218	Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS). Clinical Infectious Diseases, 2022, 75, 1971-1979.	2.9	12
219	Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland. , 2022, 152, .		3
220	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 2022, 13, 817345.	2.2	5
223	SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine. Journal of Medical Virology, 2022, 94, 3768-3775.	2.5	13
224	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. Open Forum Infectious Diseases, 2022, 9, .	0.4	62
226	Coronavirus Disease 2019 Disease Severity in Children Infected With the Omicron Variant. Clinical Infectious Diseases, 2022, 75, e361-e367.	2.9	83
227	COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia. Emerging Microbes and Infections, 2022, 11, 1262-1271.	3.0	21

#	ARTICLE	IF	CITATIONS
229	Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	8
230	Modeling the population-level impact of treatment on COVID-19 disease and SARS-CoV-2 transmission. <i>Epidemics</i> , 2022, 39, 100567.	1.5	2
231	Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada. <i>Clinical Infectious Diseases</i> , 2022, 75, 1980-1992.	2.9	92
232	It Takes Two to Tango: How the COVID-19 Vaccination Campaign in Israel Was Framed by the Health Ministry vs. the Television News. <i>Frontiers in Public Health</i> , 2022, 10, 887579.	1.3	3
233	A Folding-Based Electrochemical Aptasensor for the Single-Step Detection of the SARS-CoV-2 Spike Protein. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 19204-19211.	4.0	42
234	Advances in COVID-19 mRNA vaccine development. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 94.	7.1	177
235	Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel. <i>Nature Communications</i> , 2022, 13, 2202.	5.8	13
236	Impact of prior vaccination on clinical outcomes of patients with COVID-19. <i>Emerging Microbes and Infections</i> , 2022, 11, 1316-1324.	3.0	7
237	Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine. <i>Aids</i> , 2022, 36, 1255-1264.	1.0	13
239	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
240	Vaccine equity or health equity?. <i>Journal of Global Health Economics and Policy</i> , 0, 2, .	1.0	3
241	The Relationship between Attitudes and Satisfaction Concerning the COVID-19 Vaccine and Vaccine Boosters in Urban Bangkok, Thailand: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5086.	1.2	4
242	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. <i>Vaccines</i> , 2022, 10, 662.	2.1	17
243	SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination. <i>Microorganisms</i> , 2022, 10, 857.	1.6	8
244	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. <i>Vaccines</i> , 2022, 10, 696.	2.1	11
245	Robustness analysis for quantitative assessment of vaccination effects and SARS-CoV-2 lineages in Italy. <i>BMC Infectious Diseases</i> , 2022, 22, 415.	1.3	3
246	Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron Variant. <i>Clinical Infectious Diseases</i> , 2022, 75, 2161-2168.	2.9	35
247	Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era. <i>PLoS ONE</i> , 2022, 17, e0268050.	1.1	19

#	ARTICLE	IF	CITATIONS
249	Risk of SARS-CoV2 by vaccination status and population characteristics in Qatar. <i>Clinical Infection in Practice</i> , 2022, , 100148.	0.2	0
250	SARS-CoV-2 variants â€œ Evolution, spike protein, and vaccines. <i>Biomedical Journal</i> , 2022, 45, 573-579.	1.4	26
251	Alpha, Beta, Delta, Omicron, and SARS-CoV-2 Breakthrough Cases: Defining Immunological Mechanisms for Vaccine Waning and Vaccine-Variant Mismatch. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	14
252	Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARSâ€CoVâ€2 Omicron BA.1 variant. <i>MedComm</i> , 2022, 3, e143.	3.1	3
253	Comparison of the Clinical and Laboratory Findings and Outcomes of Hospitalized COVID-19 Patients Who Were Either Fully Vaccinated with Coronavac or Not: An Analytical, Cross Sectional Study. <i>Vaccines</i> , 2022, 10, 733.	2.1	4
255	Viral mutations, vaccine effectiveness and rapid tests â€œ COVID-19 risk management in the two largest LNG producing countries, Qatar and Australia. , 2022, 62, S291-S294.		0
256	Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose. <i>Nature Immunology</i> , 2022, 23, 940-946.	7.0	67
257	Impact of national Covid-19 vaccination Campaign, South Korea. <i>Vaccine</i> , 2022, 40, 3670-3675.	1.7	21
258	SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2022, 22, 439.	1.3	155
259	Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	16
260	Equipment-free, gold nanoparticle based semiquantitative assay of SARS-CoV-2-S1RBD IgG from fingertip blood: A practical strategy for on-site measurement of COVID-19 antibodies. <i>Talanta</i> , 2022, 246, 123498.	2.9	3
261	Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Caseâ€Control Study. <i>Vaccines</i> , 2022, 10, 779.	2.1	8
262	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
263	SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status. <i>Nature Communications</i> , 2022, 13, 2777.	5.8	8
264	SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol. <i>BMJ Open</i> , 2022, 12, e061345.	0.8	2
265	Hospitalised patients with breakthrough COVID-19 following vaccination during two distinct waves in Israel, January to August 2021: a multicentre comparative cohort study. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
267	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. <i>BMJ Global Health</i> , 2022, 7, e008684.	2.0	122
268	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1

#	ARTICLE	IF	CITATIONS
269	Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. JAMA Network Open, 2022, 5, e2213606.	2.8	65
270	Digital Marketing: A Unique Multidisciplinary Approach towards the Elimination of Viral Hepatitis. Pathogens, 2022, 11, 626.	1.2	9
271	Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study. BMJ, The, 0, , e071113.	3.0	62
272	Heterogeneous SARS-CoV-2 humoral response after COVID-19 vaccination and/or infection in the general population. Scientific Reports, 2022, 12, .	1.6	8
273	Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic. BMC Medicine, 2022, 20, .	2.3	6
274	Omicron Infection Evokes Cross-Protection against SARS-CoV-2 Variants in Vaccinees. Vaccines, 2022, 10, 808.	2.1	7
275	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England. Lancet Infectious Diseases, The, 2022, 22, 931-933.	4.6	133
276	Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Frontiers in Immunology, 2022, 13, .	2.2	30
277	Usefulness of vaccine boosters for Covid-19 in Italy and in UK and comparison between in intensive care admissions and deaths of vaccinated and unvaccinated patients. Surprises and implications. F1000Research, 0, 11, 579.	0.8	0
278	Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 0, 9, .	1.2	25
279	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	149
282	Post-vaccination outcomes in association with four COVID-19 vaccines in the Kingdom of Bahrain. Scientific Reports, 2022, 12, .	1.6	9
283	Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nature Communications, 2022, 13, .	5.8	19
284	Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. Nature Communications, 2022, 13, .	5.8	188
285	Long Term Vaccination Strategies to Mitigate the Global Impact of SARS-CoV-2 Transmission: A Modelling Study. SSRN Electronic Journal, 0, , .	0.4	2
286	Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizerâ€BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece. Vaccines, 2022, 10, 876.	2.1	16
288	Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center. Journal of Personalized Medicine, 2022, 12, 955.	1.1	9
290	Booster Doses of Anti COVID-19 Vaccines: An Overview of Implementation Policies among OECD and EU Countries. International Journal of Environmental Research and Public Health, 2022, 19, 7233.	1.2	5

#	ARTICLE	IF	CITATIONS
291	Serosurveillance after a COVID-19 vaccine campaign in a Swiss police cohort. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	4
293	Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	5
294	A Macro-Level Association of Vaccination Rate with the Number of Confirmed COVID-19 Cases in the United States and Japan. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7435.	1.2	0
295	Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study). <i>Frontiers in Immunology</i> , 0, 13, .	2.2	26
296	SARS-CoV-2 spike protein antibody titers 6 months after SARS-CoV-2 mRNA vaccination among patients undergoing hemodialysis in Japan. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 988-996.	0.7	6
297	Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. <i>BMJ, The</i> , 0, , e070102.	3.0	10
298	COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant and implications for vaccination. <i>Journal of the Royal Society Interface</i> , 2022, 19, .	1.5	60
299	Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates. <i>Nature Communications</i> , 2022, 13, .	5.8	19
300	Application of human RNase P normalization for the realistic estimation of SARS-CoV-2 viral load in wastewater: A perspective from Qatar wastewater surveillance. <i>Environmental Technology and Innovation</i> , 2022, 27, 102775.	3.0	17
301	Temporal changes in spike IgG levels after two doses of BNT162b2 vaccine in Japanese healthcare workers: Do spike IgG levels at 3 months predict levels 6 or 8 months after vaccination?. <i>PLoS ONE</i> , 2022, 17, e0263486.	1.1	0
303	Evaluating the attitudes and behavior of Hong Kong medical students toward receiving the COVID-19 vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	1
304	Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations. <i>Current Opinion in Neurology</i> , 2022, 35, 319-327.	1.8	12
305	OMICRON: Virology, immunopathogenesis, and laboratory diagnosis. <i>Journal of Gene Medicine</i> , 2022, 24, .	1.4	33
306	Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. <i>New England Journal of Medicine</i> , 2022, 387, 21-34.	13.9	368
307	Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial. <i>Emerging Microbes and Infections</i> , 2022, 11, 1910-1919.	3.0	27
308	Hospitalized Patients With Severe Coronavirus Disease 2019 During the Omicron Wave in Israel: Benefits of a Fourth Vaccine Dose. <i>Clinical Infectious Diseases</i> , 2023, 76, e234-e239.	2.9	20
309	Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1273-1278.	0.8	8
310	Comparative COVID-19 Vaccine Effectiveness over Time in Veterans. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	15

#	ARTICLE	IF	CITATIONS
312	Humoral Response to mRNA-1273 SARS-CoV-2 Vaccine in Peritoneal Dialysis Patients: Is Boostering After Six Months Adequate?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	7
313	Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	104
314	A multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study. <i>EClinicalMedicine</i> , 2022, 49, 101495.	3.2	17
315	Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in [®] , in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. <i>EClinicalMedicine</i> , 2022, 50, 101526.	3.2	20
316	Vaccination games in prevention of infectious diseases with application to COVID-19. <i>Chaos, Solitons and Fractals</i> , 2022, 161, 112294.	2.5	5
317	Effectiveness of BNT162b2 mRNA COVID-19 Third Vaccines During Pregnancy: A National Observational Study in Israel. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
318	Immunogenicity and Safety of Homologous and Heterologous Booster Vaccination of ChAdOx1 nCoV-19 (COVISHIELD [®]) and BBV152 (COVAXIN [®]) in Previous Recipients of COVISHIELD [®] or COVAXIN [®] : A Phase 4, Participant and Observer Blinded, Randomised Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
319	Effectiveness of Vaccination Against SARS-CoV-2 Omicron Variant Infection, Symptomatic Disease, and Hospitalisation: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
320	Modeling Incorporating the Severity-Reducing Long-term Immunity: Higher Viral Transmission Paradoxically Reduces Severe COVID-19 During Endemic Transition. <i>Immune Network</i> , 2022, 22, .	1.6	1
321	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
324	mRNA Booster Vaccination Enhances Antibody Responses against SARS-CoV2 Omicron Variant in Individuals Primed with mRNA or Inactivated Virus Vaccines. <i>Vaccines</i> , 2022, 10, 1057.	2.1	11
325	Duration of COVID-19 mRNA Vaccine Effectiveness against Severe Disease. <i>Vaccines</i> , 2022, 10, 1036.	2.1	2
326	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. <i>PLoS ONE</i> , 2022, 17, e0270801.	1.1	18
327	Association between Recent Usage of Antibiotics and Immunogenicity within Six Months after COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1122.	2.1	12
328	COVID-19 in children: epidemic issues and candidate vaccines. <i>Chinese Medical Journal</i> , 0, Publish Ahead of Print, .	0.9	2
329	Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	23
330	Effectiveness of COVID-19 Booster on the Risk of Hospitalization Among Medicare Beneficiaries. <i>Mayo Clinic Proceedings</i> , 2022, 97, 1780-1793.	1.4	5
331	Vaccination and variants: Retrospective model for the evolution of Covid-19 in Italy. <i>PLoS ONE</i> , 2022, 17, e0265159.	1.1	4

#	ARTICLE	IF	CITATIONS
333	Will People Accept a Third Booster Dose of the COVID-19 Vaccine? A Cross-Sectional Study in China. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	7
334	The impact of COVID-19 vaccination programme in the Republic of San Marino: Focus on effectiveness of Gam-Covid-Vac. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1636-1643.	2.8	3
335	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. <i>Vaccines</i> , 2022, 10, 1071.	2.1	14
336	Incidence and severity of SARS-CoV-2 infections in liver and kidney transplant recipients in the post-vaccination era: Real-life data from Denmark. <i>American Journal of Transplantation</i> , 2022, 22, 2637-2650.	2.6	22
337	Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults. <i>Nature Communications</i> , 2022, 13, .	5.8	18
338	COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
340	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
341	Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e470-e480.	2.0	22
342	Effectiveness and Waning of Protection With Different SARS-CoV-2 Primary and Booster Vaccines During the Delta Pandemic Wave in 2021 in Hungary (HUN-VE 3 Study). <i>Frontiers in Immunology</i> , 0, 13, .	2.2	25
343	Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records. <i>BMJ, The</i> , 0, , e071249.	3.0	31
344	COVID-19 vaccine booster hesitancy (VBH) of healthcare professionals and students in Poland: Cross-sectional survey-based study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	31
345	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11
346	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
347	Post COVID-19 condition and its potential impact on disabilityâ€”A proposal for a calculation basis for the disability insurance sector. <i>Zeitschrift Fur Die Gesamte Versicherungswissenschaft</i> , 2022, 111, 191-208.	1.2	0
348	Association of periodontal therapy, with inflammatory biomarkers and complications in COVID-19 patients: a case control study. <i>Clinical Oral Investigations</i> , 2022, 26, 6721-6732.	1.4	12
349	Effectiveness of two and three mRNA COVID-19 vaccine doses against Omicron- and Delta-Related outpatient illness among adults, October 2021-February 2022. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 975-985.	1.5	11
350	Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy. <i>HemaSphere</i> , 2022, 6, e764.	1.2	22
351	Immunological responses following the third dose of the BNT162b2 SARS-CoV-2 vaccine among Japanese healthcare workers. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1478-1482.	0.8	3

#	ARTICLE	IF	CITATIONS
352	Association of Homologous and Heterologous Vaccine Boosters With SARS-CoV-2 Infection in BBIBP-CorV Vaccinated Healthcare Personnel. <i>Cureus</i> , 2022, , .	0.2	3
353	Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Residents of US Nursing Homes Before and During the Delta Variant Predominance, December 2020â€“November 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, S147-S154.	2.9	4
354	CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	25
355	Post-vaccination antibody evaluation for nosocomial SARS-CoV-2 delta variant breakthrough infection. <i>PLoS ONE</i> , 2022, 17, e0272056.	1.1	1
356	Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 706.e1-706.e10.	0.6	27
358	COVID-19 mRNA vaccine effectiveness against hospitalisation and death in veterans according to frailty status during the SARS-CoV-2 delta (B.1.617.2) variant surge in the USA: a retrospective cohort study. <i>The Lancet Healthy Longevity</i> , 2022, 3, e589-e598.	2.0	19
359	Association between Vitamin D Serum Levels and Immune Response to the BNT162b2 Vaccine for SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 1993.	1.4	8
360	Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative caseâ€“control study among US veterans. <i>BMJ Open</i> , 2022, 12, e063935.	0.8	16
361	Effectiveness of Coronavirus Disease 2019 Vaccines Against Hospitalization and Death in Canada: A Multiprovincial, Test-Negative Design Study. <i>Clinical Infectious Diseases</i> , 2023, 76, 640-648.	2.9	7
362	Usefulness of vaccine boosters for Covid-19 in Italy and in UK and comparison between in intensive care admissions and deaths of vaccinated and unvaccinated patients. <i>Surprises and implications</i> . <i>F1000Research</i> , 0, 11, 579.	0.8	0
363	COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. <i>Nature Communications</i> , 2022, 13, .	5.8	45
364	Antibody responses and correlates after two and three doses of BNT162b2 COVID-19 vaccine. <i>Infection</i> , 2023, 51, 523-525.	2.3	2
365	Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months. <i>JAMA Network Open</i> , 2022, 5, e2226046.	2.8	11
366	Vaccines against SARS-CoV-2 variants and future pandemics. <i>Expert Review of Vaccines</i> , 2022, 21, 1363-1376.	2.0	6
367	Modelling herd immunity requirements in Queensland: impact of vaccination effectiveness, hesitancy and variants of SARS-CoV-2. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2022, 380, .	1.6	7
368	Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021â€“2022: A Naturalistic Case-Control Study in Sweden. <i>Vaccines</i> , 2022, 10, 1273.	2.1	1
369	Antibody titers among healthcare workers for coronavirus disease 2019 at 6Âmonths after BNT162b2 vaccination. <i>Vaccine</i> , 2022, , .	1.7	1
370	The effectiveness and safety of mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines among individuals with chronic kidney diseases. <i>Kidney International</i> , 2022, 102, 922-925.	2.6	15

#	ARTICLE	IF	CITATIONS
371	RK-33, a small molecule inhibitor of host RNA helicase DDX3, suppresses multiple variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
372	Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
373	Development of a COVID-19 risk assessment model for participants at outdoor music festivals: evaluation of the validity and control measure effectiveness based on two actual events in Japan and Spain. <i>PeerJ</i> , 0, 10, e13846.	0.9	5
374	Surface Inactivation of Highly Mutated SARS-CoV-2 Variants of Concern: Alpha, Delta, and Omicron. <i>Biomacromolecules</i> , 2022, 23, 3960-3967.	2.6	1
375	Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. <i>Nature Communications</i> , 2022, 13, .	5.8	49
376	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. <i>BMJ Open</i> , 2022, 12, e061584.	0.8	4
377	Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2) <i>TJ ETQq0 0 0 zqB /Overlock 10 Tf e108-e115.</i>		
378	Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
379	Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose. <i>Nature Communications</i> , 2022, 13, .	5.8	27
380	Evaluation of BNT162b2 vaccine effectiveness in Malaysia: test negative case-control study. <i>Vaccine</i> , 2022, 40, 5675-5682.	1.7	2
382	Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 2304-2314.	3.0	36
383	Longitudinal evaluation of the impact of immunosuppressive regimen on immune responses to COVID-19 vaccination in kidney transplant recipients. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
384	Young Age, Female Sex, and No Comorbidities Are Risk Factors for Adverse Reactions after the Third Dose of BNT162b2 COVID-19 Vaccine against SARS-CoV-2: A Prospective Cohort Study in Japan. <i>Vaccines</i> , 2022, 10, 1357.	2.1	4
385	Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity. <i>MBio</i> , 2022, 13, .	1.8	18
386	Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?. <i>Biomedicine and Pharmacotherapy</i> , 2022, 154, 113522.	2.5	56
387	Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. <i>International Journal of Infectious Diseases</i> , 2022, 124, 96-103.	1.5	15
388	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COVS.S SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	1.5	8
389	SARS-CoV-2 Secondary Attack Rates in Vaccinated and Unvaccinated Household Contacts during Replacement of Delta with Omicron Variant, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 1999-2008.	2.0	12

#	ARTICLE	IF	CITATIONS
390	Comparison of Waning Immunity Between Booster Vaccination and 2-Dose Vaccination With BNT162b2. <i>Immune Network</i> , 2022, 22, .	1.6	2
391	Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 0, , 1-10.	0.6	3
392	Accuracy of COVID-19 “Like Illness Diagnoses in Electronic Health Record Data: Retrospective Cohort Study. <i>JMIR Formative Research</i> , 0, 7, e39231.	0.7	2
393	Duration of immunity following full vaccination against SARS-CoV-2: a systematic review. <i>Archives of Public Health</i> , 2022, 80, .	1.0	30
394	Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers. <i>Vaccine</i> , 2022, 40, 7195-7200.	1.7	17
396	Acceptance, attitudes, and barriers of vaccine booster dose among nursing students: A multicounty survey. <i>Journal of Nursing Management</i> , 2022, 30, 3360-3367.	1.4	9
397	Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
398	Durability of Protection Post “Primary COVID-19 Vaccination in the United States. <i>Vaccines</i> , 2022, 10, 1458.	2.1	8
399	Effects of SARS-CoV-2 Alpha, Beta, and Delta variants, age, vaccination, and prior infection on infectiousness of SARS-CoV-2 infections. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
400	Duration of immune protection of SARS-CoV-2 natural infection against reinfection. <i>Journal of Travel Medicine</i> , 2022, 29, .	1.4	54
401	Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents. <i>Vaccines</i> , 2022, 10, 1474.	2.1	2
402	Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. <i>Journal of the Formosan Medical Association</i> , 2023, 122, 121-131.	0.8	9
403	Estimating Waning of Vaccine Effectiveness: a Simulation Study. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	2
404	Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection. <i>JAMA Network Open</i> , 2022, 5, e2231778.	2.8	77
405	Can live-attenuated SARS-CoV-2 vaccine contribute to stopping the pandemic?. <i>PLoS Pathogens</i> , 2022, 18, e1010821.	2.1	7
406	A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?. <i>Medicine (United States)</i> , 2022, 101, e30609.	0.4	4
407	Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	3
408	Third dose of COVID-19 mRNA vaccine appears to overcome vaccine hyporesponsiveness in patients with cirrhosis. <i>Journal of Hepatology</i> , 2022, 77, 1349-1358.	1.8	23

#	ARTICLE	IF	CITATIONS
409	Estimating conditional vaccine effectiveness. <i>European Journal of Epidemiology</i> , 2022, 37, 885-890.	2.5	2
410	Effectiveness of COVID-19 Vaccines Over Time Prior to Omicron Emergence in Ontario, Canada: Test-Negative Design Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	7
411	Breakthrough cases of Omicron and Delta variants of SARS-CoV-2 during the fifth wave in Pakistan. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
412	Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine. <i>Vaccines</i> , 2022, 10, 1613.	2.1	7
413	Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. <i>BMJ, The</i> , 0, , e072141.	3.0	82
414	Vaccine-induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	19
415	Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	17
416	Clinical scoring system to predict viable viral shedding in patients with COVID-19. <i>Journal of Clinical Virology</i> , 2022, 157, 105319.	1.6	6
417	Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. <i>Nature Communications</i> , 2022, 13, .	5.8	53
418	Estimating vaccine effectiveness against SARS-CoV-2 infection, hospitalization and death from ecologic data in Costa Rica. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	4
419	Association Between Vaccination Status and Mortality Among Intubated Patients With COVID-19-Related Acute Respiratory Distress Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2235219.	2.8	18
421	SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. <i>Nature Communications</i> , 2022, 13, .	5.8	37
422	Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study. , 2022, 1, e000104.		12
423	New Surveillance Metrics for Alerting Community-Acquired Outbreaks of Emerging SARS-CoV-2 Variants Using Imported Case Data: Bayesian Markov Chain Monte Carlo Approach. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e40866.	1.2	3
424	Measuring the impact of COVID-19 vaccination and immunity waning: A modelling study for Portugal. <i>Vaccine</i> , 2022, 40, 7115-7121.	1.7	6
425	Protection against Omicron from Vaccination and Previous Infection in a Prison System. <i>New England Journal of Medicine</i> , 2022, 387, 1770-1782.	13.9	40
426	Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1831-1841.	2.0	10
427	Real-Time Monitoring of the Effectiveness of Six COVID-19 Vaccines against Laboratory-Confirmed COVID-19 in Hungary in 2021 Using the Screening Method. <i>Vaccines</i> , 2022, 10, 1824.	2.1	6

#	ARTICLE	IF	CITATIONS
428	SARS-CoV-2â€”The Role of Natural Immunity: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6272.	1.0	12
429	Modeling the spatioâ€”temporal spread of COVIDâ€”19 cases, recoveries and deaths and effects of partial and full vaccination coverage in Canada. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
430	Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. <i>Science</i> , 2022, 378, .	6.0	141
431	Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. <i>JAMA Network Open</i> , 2022, 5, e2238871.	2.8	19
432	Surfing Corona waves â€” instead of breaking them: Rethinking the role of natural immunity in COVID-19 policy. <i>F1000Research</i> , 0, 11, 337.	0.8	0
434	Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1523.	3.8	21
435	Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. <i>BMJ, The</i> , 0, , e072065.	3.0	54
436	Will Bivalent Vaccination against COVID-19 Increase the Desire for COVID-19 Vaccination among Poles?. <i>Vaccines</i> , 2022, 10, 1658.	2.1	2
437	Commitment to protective measures during the COVID-19 pandemic in Syria: A nationwide cross-sectional study. <i>PLoS ONE</i> , 2022, 17, e0275669.	1.1	2
438	Are inhaled mRNA vaccines safe and effective? A review of preclinical studies. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 1471-1485.	2.4	11
440	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
441	Effect of Lockdowns on Hospital Staff in a COVID Center: A Retrospective Observational Study. <i>Vaccines</i> , 2022, 10, 1847.	2.1	0
442	Covid-19 Vaccine Protection among Children and Adolescents in Qatar. <i>New England Journal of Medicine</i> , 2022, 387, 1865-1876.	13.9	37
443	Postexposureâ€”vaccineâ€”prophylaxis against COVIDâ€”19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
444	Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination. <i>IScience</i> , 2022, 25, 105379.	1.9	4
445	Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: a prospective cohort study. , 2023, 8, 100106.		4
446	COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19). <i>Cancers</i> , 2022, 14, 5547.	1.7	1
447	Evaluating methodological approaches to assess the severity of infection with SARS-CoV-2 variants: scoping review and applications on Belgian COVID-19 data. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	5

#	ARTICLE	IF	CITATIONS
448	Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e063919.	0.8	8
449	Effectiveness of a third BNT162b2 mRNA COVID-19 vaccination during pregnancy: a national observational study in Israel. <i>Nature Communications</i> , 2022, 13, .	5.8	14
450	Covid-19 vaccine effectiveness during Omicron BA.2 pandemic in Shanghai: A cross-sectional study based on EMR. <i>Medicine (United States)</i> , 2022, 101, e31763.	0.4	4
451	Regulatory agencies disregard real-world effectiveness evidence on product labels beyond what is reasonable. <i>Journal of Clinical Epidemiology</i> , 2022, , .	2.4	0
453	Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort study. <i>Lancet Microbe</i> , The, 2022, 3, e944-e955.	3.4	34
454	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.	2.0	21
455	An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
456	A Tale of 2 mRNA Vaccines. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1909-1911.	1.2	0
457	The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Clinical Infectious Diseases</i> , 2023, 76, 1315-1317.	2.9	8
458	Modelling COVID-19 vaccine breakthrough infections in highly vaccinated Israelâ€™The effects of waning immunity and third vaccination dose. <i>PLOS Global Public Health</i> , 2022, 2, e0001211.	0.5	11
459	Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: a prospective test negative caseâ€™control study. <i>Lancet Regional Health - Europe</i> , The, 2023, 25, 100552.	3.0	11
460	Incidence of SARS-CoV-2 infection in hospital workers before and after vaccination programme in East Java, Indonesia â€™ aâ€™retrospective cohort study. , 2023, 10, 100130.		5
461	Drivers of and Barriers to COVID-19 Vaccine Booster Dose Acceptance in Indonesia. <i>Vaccines</i> , 2022, 10, 1981.	2.1	3
462	Mapping the Arab genome. <i>Nature Genetics</i> , 2022, 54, 1761-1763.	9.4	3
464	Antibody Responses and Reactogenicity of a Heterologous, Full-Dose Messenger RNA-1273 Booster in Heavily SARS-CoV-2â€™Exposed CoronaVac-Vaccinated Health-Care Workers in Indonesia: A Real-World Observational Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, , .	0.6	3
465	Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. <i>BMC Medicine</i> , 2022, 20, .	2.3	8
466	A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior. <i>Scientific Reports</i> , 2022, 12, .	1.6	5
467	Economic evaluation of COVID-19 rapid antigen screening programs in the workplace. <i>BMC Medicine</i> , 2022, 20, .	2.3	2

#	ARTICLE	IF	CITATIONS
468	SARS-CoV-2 antibody response to third dose vaccination in a healthy cohort. Insights in Clinical and Cellular Immunology, 2022, 6, 008-013.	0.1	1
469	Use of Whole-Genome Sequencing to Estimate the Contribution of Immune Evasion and Waning Immunity on Decreasing COVID-19 Vaccine Effectiveness. Journal of Infectious Diseases, 0, , .	1.9	2
470	An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines. Journal of Clinical Medicine, 2022, 11, 7534.	1.0	0
471	Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice. Vaccines, 2023, 11, 30.	2.1	3
472	SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. Cell Discovery, 2022, 8, .	3.1	3
474	Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan. The Lancet Regional Health - Western Pacific, 2023, 32, 100661.	1.3	5
475	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.5	1
476	Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines. International Immunology, 2023, 35, 213-220.	1.8	6
477	Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells. Communications Biology, 2022, 5, .	2.0	4
478	Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study. International Journal of Environmental Research and Public Health, 2022, 19, 16958.	1.2	1
479	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. Microbes and Infection, 2023, 25, 105082.	1.0	5
480	Effectiveness of covid-19 vaccines in adolescents and children. BMJ, The, 0, , o3018.	3.0	0
481	Real-world vaccine effectiveness of mRNA vaccines for SARS-CoV-2; a test-negative case-control study in a medium-sized clinic. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	1
482	Immune Responses to SARS-CoV-2 Infection and Vaccine in a Big Italian COVID-19 Hospital: An 18-Month Follow-Up. Vaccines, 2023, 11, 8.	2.1	3
483	Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar. Journal of Infection and Public Health, 2023, 16, 250-256.	1.9	10
484	Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up. Nature Communications, 2022, 13, .	5.8	18
485	Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology, 2023, 151, 818-831.	1.5	13
486	Structural Analysis and Epitope Prediction of S2 Domain of SARS-CoV-2, Conservation Analysis Among Major Variants. Viral Immunology, 0, , .	0.6	0

#	ARTICLE	IF	CITATIONS
487	Relationship between Anti-SARS-CoV-2 S Abs and IFN- γ Levels in the Administration of Oxygen following COVID-19 Vaccination. <i>ImmunoHorizons</i> , 2023, 7, 97-105.	0.8	0
488	Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months. <i>Lancet Infectious Diseases</i> , 2023, 23, 148-150.	4.6	20
489	Effects of Second Dose of SARS-CoV-2 Vaccination on Household Transmission, England. <i>Emerging Infectious Diseases</i> , 2023, 29, 127-132.	2.0	5
490	SARS-CoV-2 mRNA Dual Immunization Induces Innate Transcriptional Signatures, Establishes T-Cell Memory and Coordinates the Recall Response. <i>Vaccines</i> , 2023, 11, 103.	2.1	1
491	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.	1.9	1
492	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
494	Covid-19 vaccine effectiveness against general SARS-CoV-2 infection from the omicron variant: A retrospective cohort study. <i>PLOS Global Public Health</i> , 2023, 3, e0001111.	0.5	4
495	Waning of humoral immunity depending on the types of COVID-19 vaccine. <i>Infectious Diseases</i> , 2023, 55, 216-220.	1.4	5
496	S Trimer Derived from SARS-CoV-2 B.1.351 and B.1.618 Induced Effective Immune Response against Multiple SARS-CoV-2 Variants. <i>Vaccines</i> , 2023, 11, 193.	2.1	1
497	COVID-19 Vaccines—All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
498	Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device. <i>International Journal of Infectious Diseases</i> , 2023, 128, 112-120.	1.5	6
499	Dynamics of Humoral and Cellular Responses in Renal Transplant Recipients Receiving 3 Doses of SARS-CoV-2 mRNA Vaccine. <i>Transplantation</i> , 0, Publish Ahead of Print, .	0.5	4
500	Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. <i>SSRN Electronic Journal</i> , 0, .	0.4	0
501	Effectiveness of mRNA Vaccine Booster against SARS-CoV-2 Infection and COVID-19 in the Adult Population during the First Three Months of the Omicron Wave in Sicily. <i>Healthcare (Switzerland)</i> , 2023, 11, 305.	1.0	3
502	Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD [®]) and BBV152 (COVAXIN [®]): a non-inferiority phase 4, participant and observer-blinded, randomised study. , 2023, 12, 100141.		14
503	Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	3
504	Anti-SARS-CoV-2 spike IgG following injection of the third dose vaccine: A systematic review with meta-analysis of heterologous versus homologous vaccination. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2
505	Infectivity of Omicron BA.5 Comparison with Original Strain and Other Mutated Strain of SARS-CoV-2 in Japan. <i>Journal of Disaster Research</i> , 2023, 18, 4-10.	0.4	1

#	ARTICLE	IF	CITATIONS
506	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2023, 6, e2251974.	2.8	12
507	Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. <i>Eurosurveillance</i> , 2023, 28, .	3.9	0
508	Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave. <i>International Journal of Infectious Diseases</i> , 2023, 128, 347-354.	1.5	7
509	Anti-SARS-CoV-2 spike immunoglobulin G and immunoglobulin M titers decline as interval from the second inactivated vaccine dose to the onset of illness is prolonged in breakthrough infection patients. <i>Clinical Respiratory Journal</i> , 0, , .	0.6	0
510	Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	4
511	Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study. <i>Revista Espanola De Geriatria Y Gerontologia</i> , 2023, 58, 125-133.	0.2	4
512	Attitudes and concerns regarding booster dose of COVID-19 vaccine among Egyptian patients with autoimmune and rheumatic diseases: a cross-sectional survey study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2023, 16, .	1.1	0
513	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. <i>Microorganisms</i> , 2023, 11, 1015.	1.6	8
514	Impact of proactive and reactive vaccination strategies for health-care workers against MERS-CoV: a mathematical modelling study. <i>The Lancet Global Health</i> , 2023, 11, e759-e769.	2.9	2
515	Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers. <i>Vaccine: X</i> , 2023, 14, 100288.	0.9	1
516	COVID-19 vaccines effectiveness against symptomatic disease and severe outcomes, 2021-2022: a test-negative case-control study. <i>Public Health</i> , 2023, 218, 84-91.	1.4	1
517	Estimating the time-dependent effective reproduction number and vaccination rate for COVID-19 in the USA and India. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 4673-4689.	1.0	7
518	Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias. <i>American Journal of Epidemiology</i> , 2023, 192, 895-907.	1.6	6
519	Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination. <i>Clinical Immunology</i> , 2023, 248, 109248.	1.4	1
520	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. <i>Chinese Medical Journal</i> , 2023, 136, 24-33.	0.9	2
521	Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases, in Patients with Cardiac Issues, and in the Healthy Population. <i>Pathogens</i> , 2023, 12, 233.	1.2	7
522	Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0281281.	1.1	4
523	mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia. <i>Vaccine</i> , 2023, 41, 2439-2446.	1.7	3

#	ARTICLE	IF	CITATIONS
524	SARS-CoV-2 elicits non-sterilizing immunity and evades vaccine-induced immunity: implications for future vaccination strategies. <i>European Journal of Epidemiology</i> , 2023, 38, 237-242.	2.5	7
525	Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac. <i>Vaccines</i> , 2023, 11, 356.	2.1	0
526	Homologous and Heterologous Prime-Boost Vaccination: Impact on Clinical Severity of SARS-CoV-2 Omicron Infection among Hospitalized COVID-19 Patients in Belgium. <i>Vaccines</i> , 2023, 11, 378.	2.1	2
527	The accelerated waning of immunity and reduced effect of booster in patients treated with bDMARD and tsDMARD after SARS-CoV-2 mRNA vaccination. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
528	Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. <i>Lancet Respiratory Medicine</i> , the, 2023, 11, 439-452.	5.2	69
529	Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
530	Public Choice Theory: An Explanation of the Pandemic Policy Responses. <i>Studies in Public Choice</i> , 2023, , 97-132.	0.0	1
531	Occurrence and Severity of Coronavirus Disease 2019 Are Associated With Clinical Disability Worsening in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2023, 10, .	3.1	3
532	Simulating potential outbreaks of Delta and Omicron variants based on contact-tracing data: A modelling study in Fujian Province, China. <i>Infectious Disease Modelling</i> , 2023, 8, 270-281.	1.2	1
533	A Novel Mathematical Model That Predicts the Protection Time of SARS-CoV-2 Antibodies. <i>Viruses</i> , 2023, 15, 586.	1.5	7
534	Comparison of the efficacy of one, two, and third doses of BNT162b2 in patients suffering from cardiovascular diseases, respiratory diseases, and diabetes against COVID-19. <i>Pharmacia</i> , 2023, 70, 155-159.	0.4	2
535	Current Status and Prospects of Vaccines based on DDS Technology. <i>Drug Delivery System</i> , 2022, 37, 402-411.	0.0	0
536	Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France. <i>Vaccine</i> , 2023, 41, 2280-2288.	1.7	5
537	Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients. <i>Vaccines</i> , 2023, 11, 572.	2.1	3
538	Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and/or COVID-19 vaccination. <i>EBioMedicine</i> , 2023, 89, 104475.	2.7	4
539	Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents. <i>Journal of Pediatrics</i> , 2023, 257, 113371.	0.9	4
540	Higher plasma levels of thymosin- α 1 are associated with a lower waning of humoral response after COVID-19 vaccination: an eight months follow-up study in a nursing home. <i>Immunity and Ageing</i> , 2023, 20, .	1.8	1
541	Estimating immunity with mathematical models for SARS-CoV-2 after COVID-19 vaccination. <i>Npj Vaccines</i> , 2023, 8, .	2.9	0

#	ARTICLE	IF	CITATIONS
542	Variants of SARS-CoV-2: Influences on the Vaccines™ Effectiveness and Possible Strategies to Overcome Their Consequences. <i>Medicina (Lithuania)</i> , 2023, 59, 507.	0.8	5
544	Long-term adaptive response in COVID-19 vaccine recipients and the effect of a booster dose. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
545	Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 816-827.	4.6	35
546	Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	15
547	From a genome-wide screen of RNAi molecules against SARS-CoV-2 to a validated broad-spectrum and potent prophylaxis. <i>Communications Biology</i> , 2023, 6, .	2.0	3
548	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7
549	Characteristics of Decedents With COVID-19-Related Mortality in Kentucky, July 1-August 13, 2021. <i>Public Health Reports</i> , 0, , 003335492311558.	1.3	0
550	COVID-19 in Elderly Patients Receiving Haemodialysis: A Current Review. <i>Biomedicines</i> , 2023, 11, 926.	1.4	2
551	The effect of HIV on COVID-19 vaccine responses. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 135-141.	1.5	4
552	A Novel Approach to Obtain Vaccine Effectiveness Continuous Profiles. Example Case: COVID-19 in Elderly Mexicans. <i>Vaccines</i> , 2023, 11, 719.	2.1	1
553	Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis. <i>Nature Communications</i> , 2023, 14, .	5.8	31
554	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. <i>Vaccines</i> , 2023, 11, 744.	2.1	1
555	The Effect of the Immunization Schedule and Antibody Levels (Anti-S) on the Risk of SARS-CoV-2 Infection in a Large Cohort of Healthcare Workers in Northern Italy. <i>Vaccines</i> , 2023, 11, 746.	2.1	4
557	Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: A case-control study. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	6
558	Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Vaccines</i> , 2023, 11, 775.	2.1	4
559	Peri-infection titers of neutralizing and binding antibodies as a predictor of COVID-19 breakthrough infections in vaccinated healthcare professionals: importance of the timing. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1670-1675.	1.4	3
574	Modelling Singapore's Covid-19 Pandemic Using SEIRQV and Hybrid Epidemiological Models. , 2023, , 559-575.		1
658	Combat COVID-19 at National Level using Risk Stratification with Appropriate Intervention. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------